A taurine-conjugated form of hyodeoxycholic acid
Related Products
Analytical Standard(s)
31614Taurohyodeoxycholic Acid MaxSpec® Standard
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Taurohyodeoxycholic Acid (sodium salt)

Item No. 21956

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
2-[[(3α,5β,6α)-3,6-dihydroxy-24-oxocholan-24-yl]amino]-ethanesulfonic acid, monosodium salt
CAS Number
38411-85-7
Synonyms
  • Taurine Hyodeoxycholate
  • THDCA
Molecular Formula
C26H44NO6S • Na
Formula Weight
521.7
Purity
≥95%
Formulation (Request formulation change)
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 30 mg/mlDMF:PBS(pH 7.2)(1:1): 0.5 mg/mlDMSO: 20 mg/mlEthanol: 20 mg/ml
SMILES
C[C@H](CCC(NCCS([O-])(=O)=O)=O)[C@@]1([H])CC[C@@]2([H])[C@]3([H])C[C@H](O)[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@@]21C.[Na+]
InChi Code
InChI=1S/C26H45NO6S.Na/c1-16(4-7-24(30)27-12-13-34(31,32)33)19-5-6-20-18-15-23(29)22-14-17(28)8-10-26(22,3)21(18)9-11-25(19,20)2;/h16-23,28-29H,4-15H2,1-3H3,(H,27,30)(H,31,32,33);/q;+1/p-1/t16-,17-,18+,19-,20+,21+,22+,23+,25-,26-;/m1./s1
InChi Key
VNQXUJQHLHHTRC-WMWRQJSFSA-M
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $36

    Add

    5 mg

    $153

    Add

    10 mg

    $268

    Add

    25 mg

    $587

    Add
    Lipid Resource Center
    Discover Products & Resources for Lipid Research
    • High-purity lipid standards
    • Lipid roles in biology
    • Lipids in health & disease
    • Lipids for pharmaceutical development
    • Protocols, advice, & resources
    EXPLORE NOW
    Product Description

    Taurohyodeoxycholic acid (THDCA) is a taurine-conjugated form of the secondary bile acid hyodeoxycholic acid (Item No. 20294).1 THDCA decreases the size and weight of human gallstones in vitro. It increases bile flow, biliary cholesterol secretion, and biliary lipid secretion in rats.2 Co-administration of THDCA with taurochenodeoxycholic acid (TCDCA; Item No. 20275) prevents TCDCA-induced hepatotoxicity, increasing bile flow as well as biliary acid and phospholipid secretion in rats.3 THDCA also reduces myeloperoxidase activity, expression of TNF-α and IL-6, and colonic damage in a mouse model of TNBS-induced ulcerative colitis.4

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Angelico, M., Mogavero, L., Baiocchi, L., et al. Dissolution of human cholesterol gallstones in bile salt/lecithin mixtures: effect of bile salt hydrophobicity and various pHs. Scand. J. Gastroenterol. 30(12), 1178-1185 (1995).

    2. Angelico, M., Baiocchi, L., Nistri, A., et al. Effect of taurohyodeoxycholic acid, a hydrophilic bile salt, on bile salt and biliary lipid secretion in the rat. Dig. Dis. Sci. 39(11), 2389-2397 (1994).

    3. Roda, A., Piazza, F., Baraldini, M., et al. Taurohyodeoxycholic acid protects against taurochenodeoxycholic acid-induced cholestasis in the rat. Hepatology 27(2), 520-525 (1998).

    4. He, J., Liang, J., Zhu, S., et al. Protective effect of taurohyodeoxycholic acid from Pulvis Fellis Suis on trinitrobenzene sulfonic acid induced ulcerative colitis in mice. Eur. J. Pharmacol. 670(1), 229-235 (2011).

    Product Citations

    Kaffe, E., Roulis, M., Zhao, J., et al. Humanized mouse liver reveals endothelial control of essential hepatic metabolic functions. Cell 186(18), 3793-3809 (2023).